Dynavax Technologies
Dynavax Technologies is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Dynavax Technologies.
Dynavax Technologies is a company.
Key people at Dynavax Technologies.
Key people at Dynavax Technologies.
Dynavax Technologies Corporation (DVAX) is a commercial-stage biopharmaceutical company headquartered in Emeryville, California, focused on developing and commercializing innovative vaccines and immunotherapies, primarily targeting infectious diseases and immunology.[1][2] Its flagship product, HEPLISAV-B, is a hepatitis B vaccine for adults aged 18 and older, generating $154.2 million in 2023 revenue and capturing 8.7% of the hepatitis B vaccine market; the company also offers CpG 1018, an adjuvant used in HEPLISAV-B and other vaccines, alongside a pipeline including SD-101 immunotherapy, rF1V (plague vaccine in Phase 2), and Z-1018 (shingles vaccine candidate in Phase 1/2).[1][2] Dynavax serves hospitals, clinics, public health entities, the Department of Defense, Veterans Affairs, and pharmacies via wholesalers, addressing unmet needs in adult vaccination and immunotherapy with 2023 revenue of $701.1 million, net income of $154.3 million, and $187.5 million in R&D investment across 7 active clinical trials.[1][2]
Dynavax Technologies was incorporated in August 1996 as Double Helix Corporation in Berkeley, California (later relocating headquarters to Emeryville), and quickly renamed Dynavax Technologies Corporation in September 1996.[1][2] The company's early focus emerged from advancing Toll-like receptor (TLR) agonist-based technologies for vaccines and immunotherapies, leading to its IPO on February 19, 2004.[2] Pivotal moments include FDA approval of HEPLISAV-B in 2017 after prior setbacks, commercialization ramp-up, and partnerships like those with the U.S. Department of Defense, Coalition for Epidemic Preparedness Innovations, and Zhejiang Clover Biopharmaceuticals for CpG 1018 in COVID-19 vaccines, driving growth in infectious disease prevention.[1][2]
Dynavax stands out in biopharma through its proprietary CpG 1018 adjuvant platform, which enhances immune responses in vaccines like HEPLISAV-B, offering superior seroprotection rates compared to traditional hepatitis B vaccines, especially in adults and hemodialysis patients.[1][2]
Dynavax rides the wave of rising demand for novel adjuvants and adult vaccines amid global infectious disease threats, post-COVID emphasis on rapid vaccine tech, and aging populations needing shingles/hepatitis prevention.[1][2] Timing aligns with market forces like U.S. government stockpiling (e.g., plague vaccine) and international collaborations for pandemic preparedness, where CpG 1018's proven efficacy in COVID boosters amplifies influence.[2] It contributes to the biopharma ecosystem by licensing adjuvant tech, supporting partners like Clover Biopharma, and filling gaps in adult immunization rates, which lag pediatric vaccines, while influencing R&D in TLR-based therapies for oncology and autoimmunity.[1][2]
Dynavax's trajectory points to pipeline milestones like Phase 2/3 data for rF1V and Z-1018, potential HEPLISAV-B label expansions (e.g., hemodialysis), and adjuvant licensing deals amid biopharma M&A trends.[1][2] Trends like mRNA-adjuvant combos and government vaccine contracts will shape growth, potentially evolving its role from niche player to key supplier in global health security. With a $1.2B market cap and profitability, expect accelerated expansion if trials succeed, reinforcing its mission to innovate vaccines from the ground up.[1]
